Peter van Mourik

159 Personalized treatment of CF using rectal organoids Supplemental Table S1. Correlation of in vivo and in vitro response with different forskolin concentrations Forskolin concentration (μM) Organoids vs. ppFEV 1 Organoids vs. SCC n r (95% CI) p-value n r (95% CI) p-value 0.050 20 0.294 (-0.170 - 0.652) 0.21 17 -0.417 (-0.748 - 0.080) 0.10 0.128 (fig 1c,d) 21 0.610 (0.242 - 0.825) 0.003 18 -0.762 (-0.906 - -0.458) <0.001 0.320 20 0.407 (-0.044 - 0.720) 0.08 17 -0.766 (-0.911 - -0.452) <0.001 0.800 21 0.065 (-0.378 - 0.483) 0.78 18 -0.580 (-0.824 - -0.155) 0.01 ppFEV 1 , percentage of predicted forced expiratory volume in one second; SCC, Sweat Chloride Concentration Supplemental Table S2. Key resources table REAGENT or RESOURCE SOURCE IDENTIFIER Biological Samples Human rectal tissue This paper http://hub4organoids. eu/ Chemicals, Peptides, and Recombinant Proteins B27 supplement with Vitamin A Thermo Fisher Scientific: Invitrogen Cat# 17504-044 N-Acetylcysteine Sigma Aldrich Cat# A9165-25g Nicotinamide Sigma Aldrich Cat# N0636 Mouse Epithelial Growth Factor Invitrogen Cat# PMG8043-1mg TGFb type I Receptor inhibitor (A83-01) Tocris Cat# 2939 p38 MAPK inhibitor (SB202190) Sigma Aldrich Cat# S7067-25mg Calcein, AM Life Technologies: Gibco Cat# C3100MP Forskolin Sigma Cat# F3919-10mg Lumacaftor (VX-809) Selleckchem Cat# s1565 Ivacaftor (VX-770) Selleckchem Cat# s1144 Genistein Sigma Cat# 92136-10mg Curcumin Sigma Cat# C7727-500mg Deposited Data 7